New data for RA diagnostic should give Crescendo – and Myriad – a lift
This article was originally published in Clinica
Executive Summary
Myriad Genetics may have disappointed its investors earlier this month with its lackluster first fiscal quarter results, but the company can at least take comfort it had bet on the right horse when it acquired autoimmune disease testing specialist Crescendo Biosciences in February.